Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025

About this update from Pelthos Therapeutics Inc.

Company to hold a conference call at 8:00 a.m. ET DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), will hold a conference call on Thursday, November 13, 2025, at 8:00 a.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call. Pelthos management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Webcast:         https://viavid.webcasts.com/starthere.jsp?ei=1740524&tp_key=723fef088c About Pelthos Therapeutics Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com . Follow Pelthos on LinkedIn and X . Contacts Investors: Mike Moyer Managing Director, LifeSci Advisors, LLC [email protected] Media: KWM Communications Kellie Walsh [email protected] (914) 315-6072

View stock analysis, news, and events for Pelthos Therapeutics Inc.